Awaiting FDA approval.
60 million PAP smear tests are performed annually.
GTHP's biophotonic scan is more accurate and produces instant test results.
GTHP is a potential 10 bagger.
The new agreement implies that Braeburns anticipates additional trials will be needed for other dose formulations. So Braeburn extracted the rights to 98% of all other formulations for $5 million. Sunil, for good measure, stuffed 6 million shares into Rubin's buddies pockets at Braeburn and also gave back $30M that Titan would have received on approval.
Braeburn will run the six month trials and then sublicense the rights to RB or Big Pharma for a hefty royalty. Titan shareholders? They will get 1% to 2%. Yeah, great deal!
Does anybody seriously think that Braeburn, without a sales force, will market Probuphine? Braeburn is an investment fund. Sunil left so much meat on the bones that Braeburn will be able to sublicense Probuphine and collect a bigger royalty than Titan shareholders.
Where are we now? If Probuphine is approved, Titan gets a temporary small bounce. Then the reality would set in that Titan will need additional financing and that meaningful royalties won't show up for years to come.
If Probuphine is not approved, Sunil closes up shop once again.
A Mega Millions lottery ticket provides better odds.
With Sunil in charge, it's just a matter of time before he pulls the rug out from under shareholders.
There are biotechs with competent management that can be bought, some with market caps even lower than Titan's. Why anyone would hold this stock now, with the real risk of a 100% loss, is beyond me.
quest is pumping a dead horse. Titan had potential at one time. The reality is that Sunil sapped all the value out of Titan with dilution and really bad deals. quest is living in the past.
Sunil pumped "several interested parties" for quarters on end. It was assumed that Titan would come back with great partnership deals for the US and for the ROW, that Big Pharma and RB were battling for the rights.
Sunil accepted a mediocre to poor deal from Rubin's buddies, an investment/hedge fund without a sales team. The terms that were agreed to for an NDA filed drug were pathetic. It's a deal that biotechs get for preclinical drugs. Look at the recent deal that INO got with Roche for PRECLINICALS, and Roche agreed to fund all the trials and to $450M in milestones. Hey, Sunil has a preclinical: Gallium. Why doesn't he partner it? Oh, I forgot, Sunil doesn't multi task. Why doesn't Sunil start a Parkinson's trial? Oh, I forgot, the patent was disallowed and Sunil can't multi task. Why doesn't Sunil license to Big Pharma other uses of ProNeura? Oh, I forgot, Sunil can't multi task. Why doesn't Sunil partner the ROW rights to Probuphine? Oh, I forgot, he doesn't multi task.
Now Sunil is giving give-backs to an embarrassingly pathetic poor deal? ?? ??? ????
Titan would have received $45M on approval and the funds could have been used to advance another program. Under the amended agreement, Titan will receive only $15M, enough for one year of operating expenses and Sunil's and Rubin's salaries. What then? More Dilution?
The much hyped "several interested parties" deal has turned into a nothing deal. The saving grace was the modest payment on approval. Now just about all of that has vanished. Does anybody really expect Braeburn, without a sales force, to have significant sales while training doctors in the surgical procedure? Perhaps Braeburns plan is to sublicense Probuphine to RB or Big Pharma, something that Sunil should have done.
An amended NDA is needed or an Appeal needs to be filed.
If either were filed, a PR would have had to been issued since that would be a material event.
Come on, we are talking about Titan!
Sunil only knows the slow lane and how to shuffle his feet. He can't multi task.
The FDA needs to respond to an action by Titan.
How dumb would they look if they said "we change our mind or we were just kidding" six months after the CRL and Titan hasn't disagreed with the decision by filing an Appeal nor have they filed an amended NDA with the additional data that the FDA wants.
Your post is just a silly pump.
I should have pulled the trigger.
I've been F-Ued by this not so fab stock.
Going over to GTHP today.
2014 will be a monster year.
"Apple Tree Partners (ATP), a venture capital firm that invests in pharmaceuticals, biotech, medtech, and healthcare services."
What drugs do they market?
Is there a more incompetent CEO than Sunil?
or the 6 mg, 7 mg, 9 mg, 10 mg ..... implants at the low single digit royalty?
Why would Braeburn have gotten the agreement amended to include different doses if they weren't planning to market them?
This will be huge!
The biophotonics scan will replace 60 million annual PAP smear tests.
Biophotonics is noninvasive, more accurate, painless and produces instant test results.
Market cap only $40 million!!!!!!!!!!
Braeburn didn't buy any shares. The $5M was for restructuring the deal .. deferring $15 and turning it into a contingency that may never be received and agreeing to LOW SINGLE DIGIT royalties on other doses.
Sunil gave away more FREE shares .... as he did with Deerfield and Rodman.
Marc only shows up for the CCs to collect his paycheck.
He lives in NJ and has little to do with the daily operations.
He's a paid hack feeding at the trough.
They are so committed that they reduced the upfront payment by $35M and deferred it to future milestones which may never be reached.
because he's a nice guy, or, is that a "dim wit".
Braeburn knows that additional trials will be required for different doses.
Braeburn will be able to sell those doses at a small single digit royalty up to a maximum royalty of $50M.
They just saved $400M and Sunil gave away $400M.